| Patent application number | Description | Published |
|---|
| 20090041716 | CRYSTALLINE FORM OF METHYL ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1((2S)-2-((METHOXYCARBONYL)AMINO)-3-METH- YLBUTANOYL)-2-PYRROLIDINYL)-1H-IMIDAZOL-5-YL)-4-BIPHENYLYL)-1H-IMIDAZOL-2-- YL)-1-PYRROLIDINYL)CARBONYL)-2-METHYLPROPYL)CARBAMATE DIHYDROCHLORIDE SALT - The present disclosure generally relates to a crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4′-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1 H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt. The present disclosure also generally relates to a pharmaceutical composition comprising a crystalline form, as well of methods of using a crystalline form in the treatment of Hepatitis C and methods for obtaining such crystalline form. | 02-12-2009 |
| 20090203630 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS - A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. | 08-13-2009 |
| 20090312331 | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPY- LPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN - Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. | 12-17-2009 |
| 20090325988 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof - Compounds of Formula (I) | 12-31-2009 |
| 20100158862 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 06-24-2010 |
| 20100311978 | PROCESS FOR OPTIMIZING THE PARTICLE SIZE OF AN ACTIVE PHARMACEUTICAL INGREDIENT BY CRYSTALLIZATION - A process to crystallize uniform small particles of a compound of Formula (I) with narrow particle size distribution and excellent powder characteristics that facilitate the formulation process and optimal drug product performance, wherein the compound of Formula (I) is: | 12-09-2010 |
| 20110124689 | PROCESS FOR PREPARING ATAZANAVIR BISULFATE AND NOVEL FORMS - A process is provided for preparing the HIV protease inhibitor atazanavir bisulfate wherein a solution of atazanavir free base is reacted with concentrated sulfuric acid in an amount to react with less than about 15% by weight of the free base, seeds of Form A crystals of atazanavir bisulfate are added to the reaction mixture, and as crystals of the bisulfate form, additional concentrated sulfuric acid is added in multiple stages at increasing rates according to a cubic equation, to effect formation of Form A crystals of atazanavir bisulfate. | 05-26-2011 |
| 20110166352 | PROCESS FOR MAKING STERILE ARIPIPRAZOLE OF DESIRED MEAN PARTICLE SIZE - A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. | 07-07-2011 |
| 20110268697 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 11-03-2011 |
| 20120108594 | PROCESS FOR PREPARING SALTS OF 4-[[5-[(CYCLOPROPYLAMINO)CARBONYL]-2-METHYLPHENYL]AMINO]-5-METHYL-N-PROPY- LPYRROLO[2,1-f][1,2,4]TRIAZINE-6-CARBOXAMIDE AND NOVEL STABLE FORMS PRODUCED THEREIN - Processes are provided for selectively preparing novel stable crystalline salt forms, selectively and consistently, namely, preparing Form N-1 of the methanesulfonic acid salt, and Form N-1 and Form N-4 of the hydrochloric acid salt of the p38 kinase inhibitor 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide. The processes preferably employ solvent systems including formic acid/acetone and formic acid/methylethyl ketone which produce crystals having suitable flow properties and desired particle size, and solvents such as N,N-dimethylformamide and N,N-dimethylacetamide may be employed as well. | 05-03-2012 |
| 20120142715 | POLYMORPH OF [4,6-BIS(DIMETHYLAMINO)-2-(4-BENZYL)PYRIMIDIN-5-YL] - Provided is a crystalline form of the ethylenediamine salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid, processes for its preparation, pharmaceutical compositions comprising it, and methods of its use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease. | 06-07-2012 |
| 20130059866 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, | 03-07-2013 |
| 20130079359 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, | 03-28-2013 |
| 20130161848 | PROCESS FOR MAKING STERILE ARIPIPRAZOLE OF DESIRED MEAN PARTICLE SIZE - A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. | 06-27-2013 |
| 20140094486 | SOLID STATE FORMS OF HIV INHIBITOR - The invention relates to novel crystalline forms of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, the hydrochloride salt thereof, novel crystalline forms of the hydrochloride salt, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection. | 04-03-2014 |
| 20150045376 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - Piperidino-dihydrothienopyrimidine sulfoxides of formula I | 02-12-2015 |
| 20150148322 | NOVEL PIPERIDINO-DIHYDROTHIENOPYRIMIDINE SULFOXIDES AND THEIR USE FOR TREATING COPD AND ASTHMA - The invention relates to novel piperidino-dihydrothienopyrimidine sulfoxides of formula I, | 05-28-2015 |
| Patent application number | Description | Published |
|---|
| 20100136435 | SECONDARY BATTERY AND MANUFACTURING METHOD OF THE SAME - Disclosed is a secondary battery including (i) a cathode; (ii) an anode; (iii) a separator; and (iv) a gel polymer electrolyte composition including an electrolyte solvent, an electrolyte salt, and a polymerizable monomer, wherein a polymerization initiator is coated or added on at least one battery device element in contact with the gel polymer electrolyte composition. Also, the secondary battery including a cathode, an anode, a separator, and a gel polymer electrolyte is manufactured by the steps of: coating or adding a polymerization initiator on/to at least one battery device element in contact with the gel polymer electrolyte; inserting the cathode, the anode, and the separator into a battery case; and forming the gel polymer electrolyte by injecting a gel polymer electrolyte composition including an electrolyte solvent, an electrolyte salt, and a polymerizable monomer into the battery case, and carrying out polymerization. | 06-03-2010 |
| 20100297510 | LITHIUM SECONDARY BATTERY WITH IMPROVED CELL CHARACTERISTICS - Disclosed herein is a lithium secondary cell including 20 to 100 wt. % of lithium transition metal oxide represented by a formula of Li | 11-25-2010 |
| 20110183216 | NON-AQUEOUS ELECTROLYTE AND SECONDARY BATTERY COMPRISING THE SAME - Disclosed is a non-aqueous electrolyte including an electrolyte salt and an electrolyte solvent, the non-aqueous electrolyte further including a compound containing both a carboxy group and a (meth)acrylic group, and a secondary battery including the non-aqueous electrolyte. The use of the compound containing both the carboxy group and the (meth)acrylic group as a component for an electrolyte significantly reduces the increase of battery thickness at high temperature storage. | 07-28-2011 |
| 20130130105 | NOVEL ELECTRODE ACTIVE MATERIAL AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME - Disclosed are an electrode active material for lithium secondary batteries, comprising at least one selected from compounds represented by the following formula 1, and a lithium secondary battery comprising the same. | 05-23-2013 |
| 20150236335 | METHOD OF MANUFACTURING SECONDARY BATTERY - Disclosed is a method of manufacturing a secondary battery, built in a battery case, having an electrode assembly impregnated with an electrolyte solution, the method including:
| 08-20-2015 |
| 20150244016 | METHOD OF MANUFACTURING SECONDARY BATTERY - Disclosed is a method of manufacturing a secondary battery wherein an electrode assembly impregnated with an electrolytic solution is embedded in a battery case,
| 08-27-2015 |
| 20150280233 | NOVEL ELECTRODE ACTIVE MATERIAL AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME - Disclosed are an electrode active material for lithium secondary batteries, comprising at least one selected from compounds represented by the following formula 1, and a lithium secondary battery comprising the same. | 10-01-2015 |
| 20150280272 | METHOD OF MANUFACTURING SECONDARY BATTERY - Disclosed is a method of manufacturing a secondary battery, built in a battery case, having an electrode assembly impregnated with an electrolyte solution, the method including:
| 10-01-2015 |
| Patent application number | Description | Published |
|---|
| 20110280198 | MOBILE TERMINAL AND CONTROL METHOD THEREOF - A mobile terminal includes a controller to establish a connection with a packet data network through a wireless communication unit. The controller selects one of a plurality of timer values that are respectively mapped to multiple applications for transmitting/receiving packet data through the connection based on a predetermined priority, operates a timer based on the selected timer value, and controls the connection based on the timer. | 11-17-2011 |
| 20120309464 | MOBILE TERMINAL - A mobile terminal and a method of controlling the mobile terminal are disclosed. In the mobile terminal, at least one second application executable in a second operating system different from a first operating system can be searched and provided among at least one first application executable in the first operating system. Accordingly, it is possible to provide a user interface for efficiently managing applications so as to be appropriate for various operating systems. | 12-06-2012 |
| 20130179403 | MOBILE TERMINAL AND CONTROLLING METHOD THEREOF - A mobile terminal and controlling method thereof are disclosed, by which restoration and backup operations are performed for the mobile terminal. For example, the mobile terminal includes a controller performing a backup operation and a restoration operation on the mobile terminal, the controller including an application module for activating a backup restoration application and at least one or more applications; and a Linux kernel module for managing a basic hardware function of the mobile terminal, the Linux kernel module including a backup restoration service unit having an access authority for accessing a file system of each of the at least one or more applications, wherein the backup restoration application accesses the file system of each of the at least one or more applications and then performs the backup and restoration operations on data of each of the at least one or more applications. | 07-11-2013 |
| 20130191686 | MOBILE TERMINAL AND CONTROLLING METHOD THEREOF - A mobile terminal and controlling method thereof are disclosed, by which restoration and backup operations are performed for the mobile terminal. The present invention includes backing up data for at least one application included in a backup target terminal and restoring the data for the at least one application in a restoration target terminal, the restoring including the performing a basic restoration operation on the data related to the at least one application, determining whether a previously provided restoration error occurs in a data restoring process for a specific application among the at least one or more applications, and performing a restoration operation corresponding to the restoration error in accordance with a result of the determining. | 07-25-2013 |
| 20150233038 | LAUNDRY TREATING APPARATUS - The laundry treating apparatus includes a door to open and close the introduction port about a first rotational or a second rotational axis which is different from first rotational axis. A first switching unit is provided in the door to allow rotation of door about the first rotational axis, and a second switching unit is provided in the door to allow rotation of the door about the second rotational axis. A lock fixes a position of at least one of the first switching unit or second switching unit when the door opens the introduction port. A damper is also provided. As can be appreciated, the mechanism used for the laundry apparatus may be applicable to other home appliances or non-home appliances where two different rotational axes may be needed to open and close a door. | 08-20-2015 |
